TNGX Q2 2021 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+258.5% YoY

Gross Profit

$18M97.5% margin

Operating Income

-$5M-25.1% margin

Net Income

-$4M-24.8% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+184.3%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$217M

Total Liabilities

$162M

Stockholders' Equity

$55M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$5M	+258.5%
Gross Profit	$18M	-$6M	+391.7%
Operating Income	-$5M	-$8M	+46.0%
Net Income	-$4M	-$8M	+46.5%